Introduction
============

Sexual dysfunction in women is characterized by persistent and recurrent problems in sexual response or desire, which cause affliction and affect their relationship with their partner.[@b1-cmwh-7-2014-045],[@b2-cmwh-7-2014-045] Sexual dysfunctions may occur at any age and affect roughly 40% of women at some point in their lifetime, with 12% of women reporting afflictive sexual problems.[@b3-cmwh-7-2014-045]

There are different types of sexual dysfunctions, characterized as (1) sexual interest/arousal disorder; (2) orgasmic disorder; and (3) genitopelvic pain/penetration disorder.[@b4-cmwh-7-2014-045] It is important to explain to the patient that transient sexual problems are common; however, if the problem persists over months or causes affliction to the patient or their partner, then the cause of the dysfunction should be investigated.[@b5-cmwh-7-2014-045],[@b6-cmwh-7-2014-045]

There are several risk factors that may contribute to the emergence of female sexual dysfunction. These include the patient's well-being; important events in romantic relationships; partner's sexual problems; gynecological factors including childbirth, hysterectomy, vaginal pain, or pelvic pain; urinary tract alterations; and drug side effects (use of beta blockers, anti-depressant, or anti-psychotic drugs).[@b7-cmwh-7-2014-045]--[@b11-cmwh-7-2014-045]

Several therapeutic alternatives are used in the treatment of female sexual dysfunction; however, it is important to identify any possible contributing physical and emotional factors before beginning treatment.[@b9-cmwh-7-2014-045],[@b11-cmwh-7-2014-045],[@b12-cmwh-7-2014-045] Therapeutic approaches include stress management and management of any relationship problems, treatment of vaginal dryness, dyspareunia, and investigation of possible drug side effects.[@b10-cmwh-7-2014-045],[@b11-cmwh-7-2014-045] The use of testosterone in the form of gels, creams, ointments, or in oral form is not recommended for pre-menopausal women, and carry the risk of side effects in addition to containing very high doses of testosterone.[@b13-cmwh-7-2014-045]--[@b16-cmwh-7-2014-045] The use of medications for erectile dysfunction has proven to be largely ineffective.[@b9-cmwh-7-2014-045],[@b15-cmwh-7-2014-045],[@b17-cmwh-7-2014-045] Dehydroepiandrosterone (DHEA) has been shown to be effective in improving sexual interest and satisfaction among women with adrenal insufficiency; however, the benefit of supplementation in women with normal adrenal function has not been confirmed.[@b18-cmwh-7-2014-045]--[@b20-cmwh-7-2014-045]

In this study, we evaluated the use of *Tribulus terrestris* extract to treat female sexual dysfunction. *T. terrestris* is a plant belonging to the *Zygophyllacea* family, with many common names including caltrop, cat's head, and bindii. The leaves and roots are used for medicinal purposes in traditional medicine in India and China and were also in use in ancient Greece.[@b21-cmwh-7-2014-045]

Objectives
==========

The primary study objective was to evaluate the efficacy of *T. terrestris* extract in female sexual dysfunction. The secondary objective was to evaluate the safety of the extract.

Material and Methods
====================

This was a qualitative--quantitative study performed at Hospital das Clínicas de Teresópolis (Teresópolis---RJ, Brazil). Subjects were included based on inclusion and exclusion criteria, followed by hospital records verification. Inclusion criteria for female patients are that they should be of reproductive age (over 18 years old), with a clinical presentation of sexual dysfunction, who were treated with tablets containing 250 mg *T. terrestris* extract (brand name Androsten^®^) at the dose of 1 tablet three times per day for a period of 90 days. The study protocol was evaluated and approved by the Fundação Educacional Serra dos Órgãos Ethical Committee (approval no. 172.071). The research complied with the principles of the Declaration of Helsinki. All subjects gave their written, informed consent to participate in the research.

Exclusion criteria were pregnant or breastfeeding women, patients presenting hypersensitivity to any component of the study medication, and any other diseases or conditions that, in the opinion of the investigator, exclude the patient from the study. All study data were recorded in the clinical research form, in which subjects were identified using 3-digit sequential numbers.

In addition to physical examination results (vital signs, weight, body mass index \[BMI\]), safety analysis included the following laboratory test results: complete blood count, amylase, glucose and fasting glucose, serum prolactin, follicle-stimulating hormone, leutenizing hormone, thyroid-stimulating hormone, serum potassium, blood urea nitrogen, serum creatinine, total and fractionated billirrubins, alkaline phosphatase, aspartate aminotransferase, and alanine aminotransferase. Occurrence and severity of adverse events were also included in the safety analysis. The primary safety and tolerability measures included any changes in vital signs and physical examination in relation to pretreatment, any changes in clinical laboratory examinations in relation to pretreatment, and the occurrence of adverse events after the first dose of study medication. Any laboratory examinations out of reference range were recorded as adverse events. The secondary safety measure was the evaluation of overall tolerability of the study medication performed post-treatment by the study physician, using the same classifications of "Very Good", "Good", "Fair", or "Poor" as were used for the overall efficacy assessment.

The primary efficacy analysis included results of the Female Sexual Function Index (FSFI), a validated self-report measure of female sexual function. This is a 19-item questionnaire that is subdivided into six domains: desire, arousal, lubrication, orgasm, satisfaction, and pain. The scoring system followed the instructions given by the authors who developed and validated the questionnaire. The maximum possible score is 36 points and the minimum possible score is 2 points.[@b22-cmwh-7-2014-045]

Secondary efficacy measures included the Patient and Physician Assessments, in which both the subject and the physician rated the patient's overall condition on a scale of 1--10 points, with "1" corresponding to the worst assessment and "10" the best. The study physician also evaluated the overall efficacy and safety of the study medication as "Very Good", "Good", "Fair", or "Poor". DHEA levels together with total and free testosterone were also included in the efficacy analysis (reference ranges: DHEA: 15--170 ng/mL; serum testosterone: 3--63 ng/dL; free testosterone: 2--45 pmol/mL).

At the end of the treatment period, subjects who completed the treatment cycle were asked to rate their willingness to continue treatment on a scale of 1 (very unwilling) to 10 (very willing).

The clinical research form was filled, coded, and the data were analyzed using GraphPad Prism version 5.1 software. Frequency tables were generated and central tendency measures were calculated (mean, median, mode). As appropriate, we used the Student's *t*-test or the repeated-measures analysis of variance (ANOVA) for continuous variables and Fisher's test or the *χ*^2^ test for categorical variables (α = 0.05). Results were compared between each assessment and throughout the study.

Results
=======

A total of 144 subjects were included in the initial analysis. Mean patient age was 41.01 years (±7.07). Sixty subjects (41.67%) were married, while 55 (38.19%) were divorced, 22 (15.28%) were single, and 7 (4.86%) were widows. Ethnicity (self-reported) was as follows: Asian (*n* = 5), Caucasian (*n* = 60), Black (*n* = 26), and mulatto (*n* = 53). The mean height of the total subjects was 161 cm (±5.97).

The relevant medical history including use of contraceptives, reproductive, and menstrual information together with data on depression is summarized in [Table 1](#t1-cmwh-7-2014-045){ref-type="table"}.

Mean DHEA level at pretreatment was 57.83 ng/mL (±30.11), while there was a statistically significant (*P* \< 0.0001) increase to 67.18 ng/mL post-treatment. Mean serum testosterone levels were 24.21 ng/dL (±13.17) at pretreatment, while at post-treatment, the levels decreased to a mean of 22.65 ng/dL (±11.58), although this change was not statistically significant (*P* = 0.284). There was a statistically significant reduction in mean free testosterone post-treatment, 7.74 pmol/L (±3.906), in relation to pretreatment values of 7.83 pmol/L (±4.67) (*P* \< 0.0001).

FSFI scores improved among 106 (88.33%) subjects at the end of the treatment period, while 14 subjects (11.67%) had decreased total scores compared to pretreatment values ([Fig. 1](#f1-cmwh-7-2014-045){ref-type="fig"}). There was a statistically significant improvement in the total FSFI score (*t* = 6.835; df = 119; *P* \< 0.0001). Splitting the sample into "responders" and "non-responders" and defining improvement as ≥20% increase in FSFI score, a total of 37 patients (30.83%) can be classified as "responders".

[Table 2](#t2-cmwh-7-2014-045){ref-type="table"} summarizes the FSFI scores showing both the total scores and those of the individual domains. Statistically significant (*P* \< 0.005) improvements were seen in the following domains: desire, arousal, orgasm, and satisfaction. The most significant improvement was seen in the desire domain with an increase in the mean score of 1.84 points, with 85% of patients showing ≥20% score improvements in relation to pretreatment values.

There were statistically significant improvements (*P* \< 0.0001) in the scores of the Patient and Physician Assessments ([Fig. 2](#f2-cmwh-7-2014-045){ref-type="fig"}). At pretreatment, no scores above 5 points on the 1--10 point scales were recorded in either assessment, while post-treatment, 36 patients had scores \>6 points in the Patient Assessment and 25 patients had scores \>6 points in the Physician Assessment.

The adverse events reported during the treatment period are summarized in [Table 3](#t3-cmwh-7-2014-045){ref-type="table"}.

[Table 4](#t4-cmwh-7-2014-045){ref-type="table"} summarizes the results of the physical examination performed pre- and post-treatment. No significant changes were recorded post-treatment.

Discussion
==========

The results show that the treatment was effective in terms of improvement in the FSFI questionnaire, with the majority of patients showing improved post-treatment scores together with statistically significant improvements in the total score of the questionnaire as well as in most of the individual domain scores. Although side effects were reported, there were no reports of serious adverse effects during the treatment period. The safety evaluations including laboratory tests and physical examination results did not undergo significant alterations during the treatment period.

Overall, *T. terrestris* has a good safety profile; previously reported side effects include irritation of the gastric mucosa and gastric reflux. The side effects reported during the treatment period do reflect this information, with an overwhelming majority of side effects related to the gastrointestinal tract.[@b23-cmwh-7-2014-045],[@b24-cmwh-7-2014-045] However, these effects were transient and, as mentioned previously, no serious adverse effects were reported.

The assessment of the female patient presenting with sexual dysfunction should take into account a wide variety of factors, including an important emotional component. Interestingly, during pretreatment assessment, we observed a relatively high number of patients self-reporting depression during the assessment of medical history, a finding that reflects the data present in the literature.[@b25-cmwh-7-2014-045],[@b26-cmwh-7-2014-045]

*T. terrestris* is often used in the treatment of infertility, decreased libido, and erectile dysfunction. It is also used among athletes to increase muscle resistance and improve performance in sports, although scientific evidence to support this effect is lacking.[@b27-cmwh-7-2014-045]--[@b31-cmwh-7-2014-045] The active components of *T. terrestris* include the steroidal glycoside saponins furostanol and spirostanol, which are found in the leaves of the plant.[@b27-cmwh-7-2014-045]

Protodioscin is a chemical substance derived from the *T. terrestris* plant that has been confirmed to increase sexual desire and improve erections by means of conversion of protodioscin to DHEA.[@b29-cmwh-7-2014-045],[@b32-cmwh-7-2014-045] In animal studies, increased testosterone levels along with increased dehydrotestosterone and DHEA are suggestive of aphrodisiac activity.[@b27-cmwh-7-2014-045]--[@b31-cmwh-7-2014-045] The aphrodisiac pro-erectile properties were co-related with a release of nitric oxide from nerve endings enervating the corpus cavernosum of the penis.[@b24-cmwh-7-2014-045] However, the literature is lacking additional studies to confirm these effects.[@b30-cmwh-7-2014-045],[@b33-cmwh-7-2014-045] Indeed, our results showing a statistically significant increase in DHEA among the treated patients are interesting as this effect can also be observed among treated female subjects.

However, the lack of correlation between increasing DHEA levels with both free testosterone and serum testosterone levels is confounding. Contrary to expectations,[@b34-cmwh-7-2014-045],[@b35-cmwh-7-2014-045] mean testosterone levels decreased among the total treated subjects, despite the presence of a clinical response. It may be because the DHEA levels in women have a greater impact on FSFI domains in relation to testosterone, explaining our positive results. A larger, prospective, randomized, comparative study would likely provide further insight into the effect of *T. terrestris* extract on testosterone levels in women. It may also be of interest to examine the effects of different doses of *T. terrestris* extract in future study.

Conclusion
==========

The co-occurrence of enhanced female sexual function and increased DHEA levels is suggestive of physiological alterations underlying clinical improvement following treatment. Our results strongly support the safety and effectiveness of *T. terrestris* extract in the treatment of female sexual dysfunction.
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![Mean total FSFI scores from pre- and post-treatment. There was a statistically significant improvement in the mean total FSFI score (*t* = 6.835; df = 119; *P* \< 0.0001), from 16.57 (±4.49) at pretreatment to 19.93 (±3.89) at post-treatment.](cmwh-7-2014-045f1){#f1-cmwh-7-2014-045}

![Patient and physician overall assessment scores from pre- and post-treatment. There were statistically significant (*P* \< 0.0001) improvements in both patient and physician assessments post-treatment in relation to pretreatment values.](cmwh-7-2014-045f2){#f2-cmwh-7-2014-045}

###### 

Medical history.

  HISTORY                              YES   NO
  ------------------------------------ ----- -----
  Previous use of contraceptives       126   18
  Previous pregnancy                   74    70
  History of miscarriage or abortion   26    118
  Intermenstrual bleeding              25    119
  Amenorrhea                           9     135
  Dysmenorrhea                         81    63
  History of depression                42    102

**Note:** Data are *n*.

###### 

FSFI scores.

  DOMAIN         MINIMUM SCORE   MAXIMUM SCORE   PRETREATMENT SCORE   POST-TREATMENT SCORE   STATISTICALLY SIGNIFICANT CHANGE
  -------------- --------------- --------------- -------------------- ---------------------- ----------------------------------
  Desire         1.2             6.0             2.51                 4.35                   Yes (*P* \< 0.0001)
  Arousal        0               6.0             2.43                 3.09                   Yes (*P* \< 0.0001)
  Lubrication    0               6.0             3.16                 3.18                   No (*P* = 0.843)
  Orgasm         0               6.0             2.75                 3.08                   Yes (*P* = 0.0014)
  Satisfaction   0.8             6.0             2.90                 3.45                   Yes (*P* \< 0.0001)
  Pain           0               6.0             2.82                 2.77                   No (*P* = 0.67)
  **Total**      **2.0**         **36.0**        **16.57**            **19.93**              Yes (*P* \< 0.0001)

**Note:** Data are *n*.

###### 

Adverse events.

  DIAGNOSIS              n   SEVERITY (n)                         CAUSALITY: RELATION TO STUDY DRUG (n)
  ---------------------- --- ------------------------------------ ---------------------------------------
  Abdominal discomfort   6   Moderate (4), Mild (2)               Likely (6)
  Abdominal distension   4   Moderate (2), Mild (2)               Unknown (1), Likely (3)
  Abdominal pain         8   Severe (4), Moderate (3), Mild (1)   Unknown (3), Likely (5)
  Diarrhea               2   Mild (2)                             Unknown (1), Likely (1)
  Eructation             3   Mild (2), Moderate (1)               Unknown (1), Likely (2)
  Flatulence             1   Moderate                             Unknown
  Gastric upset          6   Moderate (1), Brando (5)             Unknown (1), Likely (5)
  Halitosis              1   Moderate                             Likely
  Headache               4   Moderate (2), Mild (2)               Unknown (3), Likely (1)
  Insomnia               4   Severe (1), Moderate (1), Mild (2)   Unknown (3), Likely (1)
  Irritability           8   Moderate (5), Mild (3)               Unknown (2), Likely (6)
  Light sleep            1   Moderate                             Unknown
  Memory loss            1   Mild                                 Unknown
  Mood swings            1   Mild                                 Unknown
  Nausea                 2   Mild                                 Likely (2)
  Nightmares             1   Severe                               Unknown
  Oily skin              2   Moderate (1), Mild (1)               Unknown (2)
  Polyuria               1   Moderate                             Unknown
  Pruritis               1   Moderate                             Unknown

**Abbreviation:** *n*, number of subjects.

###### 

Physical examination.

  VARIABLE                          PRETREATMENT RESULT   POST-TREATMENT RESULT   CHANGE FROM PRETREATMENT?
  --------------------------------- --------------------- ----------------------- ---------------------------
  Weight (kg)                       64.51 (±9.81)         64.30 (±9.46)           No (*P* = 0.7991)
  BMI                               24.91 (±3.58)         24.86 (±3.42)           No (*P* = 0.8795)
  Systolic blood pressure (mmHg)    120.7 (±7.34)         120.5 (±7.70)           No (*P* = 0.7183)
  Diastolic blood pressure (mmHg)   78.2 (±9.2)           77.96 (±9.58)           No (*P* = 0.6604)
  Heart rate (bpm)                  66.56 (±5.97)         66.69 (±5.93)           No (*P* = 0.3247)

**Note:** Data are means (±SD).
